Paper Details

  1. Home
  2. Paper Details

Role of HMGB1 in Chemotherapy-Induced Peripheral Neuropathy.

Author: KawabataAtsufumi, SekiguchiFumiko

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review focuses on the role of high mobility group box 1 (HMGB1) in chemotherapy-induced peripheral neuropathy (CIPN). HMGB1, a pro-nociceptive mediator released extracellularly, plays a key role in CIPN development. Soluble thrombomodulin (TMα) degrades HMGB1 and shows potential for CIPN prevention.
Paper Details　
Original Abstract of the Article :
Chemotherapy-induced peripheral neuropathy (CIPN), one of major dose-limiting side effects of first-line chemotherapeutic agents such as paclitaxel, oxaliplatin, vincristine, and bortezomib is resistant to most of existing medicines. The molecular mechanisms of CIPN have not been fully understood. H...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796379/

データ提供：米国国立医学図書館（NLM）

HMGB1: A Key Player in Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy, a vital tool in cancer treatment, can sometimes have unintended consequences, including chemotherapy-induced peripheral neuropathy (CIPN). This research sheds light on the role of HMGB1, a nuclear protein, in the development of CIPN, a debilitating side effect of chemotherapy. The study explores the molecular mechanisms of CIPN and investigates the potential of targeting HMGB1 as a strategy for preventing this complication.

Targeting HMGB1 for Improved Chemotherapy Tolerance

This study suggests that HMGB1 plays a critical role in the development of CIPN. The research reveals that soluble thrombomodulin (TMα), which degrades HMGB1 in a thrombin-dependent manner, effectively prevents CIPN in rodent models and in patients undergoing oxaliplatin-based chemotherapy. These findings point towards the potential for developing new drugs that inhibit the HMGB1 pathway to prevent CIPN.

Reducing the Burden of Chemotherapy Side Effects

This research could lead to the development of strategies that mitigate the debilitating side effects of chemotherapy, improving patients' quality of life during treatment. Imagine a desert landscape where the path to cancer remission is paved with the challenges of CIPN. This research offers a new oasis, providing insights into potential strategies to prevent this complication.

Dr.Camel's Conclusion

This study unravels the intricate role of HMGB1 in chemotherapy-induced peripheral neuropathy, offering a promising avenue for preventing this debilitating side effect. It's like discovering a hidden oasis in the desert, providing a new perspective on how to navigate the challenges of cancer treatment.
Date :
  1. Date Completed 2021-04-02
  2. Date Revised 2021-04-02
Further Info :

Pubmed ID

33396481

DOI: Digital Object Identifier

PMC7796379

Related Literature

Article Analysis
・Side Effects of bortezomib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.